Form 8-K

8-K — ORAGENICS INC

Accession: 0001493152-26-021627

Filed: 2026-05-07

Period: 2026-05-07

CIK: 0001174940

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001174940

2026-05-07

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934.

Date

of Report: May 7, 2026

(Date

of earliest event reported)

Oragenics,

Inc.

(Exact

name of registrant as specified in its charter)

001-32188

59-3410522

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

Number)

9015

Town Center Parkway,

Suite

143

Lakewood

Ranch, Florida

34202

(Address

of principal executive offices)

(Zip

Code)

813-286-7900

(Registrant’s

telephone number, including area code)

(Former

Name or Former Address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock

OGEN

NYSE

American

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM

8.01. OTHER INFORMATION.

May 7, 2026, Oragenics, Inc. (the “Company”) issued a press release announcing that it has signed a Letter of Intent

(“LOI”) with Sigyn Therapeutics, Inc. (“Sigyn”) to license CardioDialysis™, an extracorporeal

blood purification technology designed to enable broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream.

copy of the Press Releases is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

ITEM

9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d)

Exhibits

Exhibit

No.

Description

99.1

Press Release dated May 7, 2026.

104

Cover

page Interactive Data File (embedded in the cover page formatted in Inline XBRL)

SIGNATURES

accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,

thereunto duly authorized on this 7th day of May 2026.

ORAGENICS,

INC.

(Registrant)

BY:

/s/

Janet Huffman

Janet

Huffman

Chief

Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Oragenics

Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

The

Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation

on Both Sides of the Blood-Brain Barrier

Sarasota,

FL and San Diego, CA — May 7, 2026 — Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”),

a clinical-stage biopharmaceutical company pioneering neurological therapeutics, and Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn”),

a developer of extracorporeal therapies, today announced the signing of a Letter of Intent (“LOI”) under which Oragenics

expects to license from Sigyn, certain disease indications of CardioDialysis™, a blood purification technology that enables the

broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream.

Under

the terms of the proposed license agreement, Oragenics would receive an exclusive license from Sigyn to develop and commercialize CardioDialysis™

for the treatment of Traumatic Brain Injury (TBI) and other chronic neurodegenerative diseases.

Strategic

Rationale: Targeting TBI Inflammation on Both Sides of the Blood-Brain Barrier

Oragenics

is currently advancing ONP-002, a first-in-class intranasal neurosteroid in Phase IIa clinical trials for concussion and mild traumatic

brain injury (mTBI). ONP-002 is designed to cross the blood-brain barrier and directly address the neuroinflammation and oxidative stress

that drive TBI-related damage within the brain.

CardioDialysis™

addresses TBI-induced inflammation from a complementary direction — outside the brain — by purifying the bloodstream of inflammatory

and pathogenic molecules that accumulate systemically following a TBI event. Together, the two therapeutic approaches would represent

a dual-modality strategy designed to attack the inflammatory cascade of TBI at both the central and peripheral levels simultaneously.

There

are currently no FDA-approved pharmacological treatments for concussion or mTBI. Oragenics believes this multi-pronged approach could

represent a significant advancement in the standard of care for the estimated 69 million individuals worldwide who suffer a brain injury

each year.

“This

letter of intent reflects our commitment to building a comprehensive TBI platform — one that addresses the full biology of brain

injury, not just symptoms. While ONP-002 targets neuroinflammation directly within the brain, CardioDialysis™ offers a powerful

complementary approach to clearing the systemic inflammatory burden that follows a TBI event. We believe combining these two strategies

has the potential to redefine recovery outcomes for millions of patients who currently have no approved treatment options.” stated

Oragenics’ Chief Executive Officer, Janet Huffman

“Beyond

the benefit offered to our shareholders, we believe the proposed transaction will position Oragenics as the only Company with therapeutic

strategies to directly target TBI-induced inflammation on both sides of the blood-brain barrier,” stated Sigyn Therapeutics CEO,

Jim Joyce.

“In

the future, we envision the possibility of ONP-002 and CardioDialysis™ being synergistically combined to accelerate TBI recovery

and reduce long-term adverse events,” concluded Joyce.

Summary

of LOI Terms

The

proposed transaction is structured as an exclusive, assignable license of the CardioDialysis™ technology for use in the agreed

Target Markets. Key terms of the LOI include:

Consideration:

Oragenics expects to issue 3,250,000 shares of a new class of restricted preferred stock to Sigyn, convertible into Oragenics common

stock on a one-to-one basis, subject to NYSE American rules and shareholder approval conditions.

Royalty:

Oragenics expects to pay a 3% royalty on revenue from sales of the licensed technology following FDA market clearance, for a period

of six years from the date of first commercial sale per approved indication and country.

Target

Closing: 90 days or sooner from the effective date of the LOI, subject to completion of due diligence, board approvals, an independent

third-party valuation, and other customary closing conditions.

Exclusivity:

Sigyn has agreed not to license the CardioDialysis™ technology to third parties for the proposed Target Markets during the

exclusivity period.

The

LOI is non-binding except for certain provisions including exclusivity, confidentiality, and governing law. The completion of a definitive

agreement remains subject to due diligence satisfactory to Oragenics, board approvals by both companies, NYSE American continued listing

compliance, and other customary closing conditions.

About

CardioDialysis™

CardioDialysis™,

developed by Sigyn Therapeutics, is an extracorporeal blood purification technology engineered to enable broad-spectrum clearance of

inflammatory cytokines, endotoxins, and other pathogenic molecules from the bloodstream. The technology is designed to leverage naturally

occurring pressure dynamics to filter and purify blood plasma through a proprietary cartridge system, with a potential profile that distinguishes

it from conventional large-scale plasmapheresis approaches. Sigyn Therapeutics is developing CardioDialysis™ for a range of serious

inflammatory conditions.

About

Oragenics, Inc.

Oragenics,

Inc. (NYSE American: OGEN) is a clinical-stage biopharmaceutical company focused on pioneering neurological therapeutics for patients

with unmet medical needs. The Company’s lead asset, ONP-002, is a first-in-class intranasal neurosteroid in Phase IIa clinical

trials for the treatment of concussion and mild traumatic brain injury — a condition affecting an estimated 69 million people worldwide

annually for which no FDA-approved pharmacological treatment currently exists. Delivered via a proprietary intranasal device, ONP-002

is designed to bypass the blood-brain barrier to directly reduce neuroinflammation and oxidative stress at the source of injury. For

more information, visit www.oragenics.com.

About

Sigyn Therapeutics™

Sigyn

Therapeutics is the developer of CardioDialysis, a next-generation blood purification technology that enables continuous broad-spectrum

clearance of inflammatory and pathogenic molecules from the bloodstream. Within the emerging field of subtractive medicine, CardioDialysis

is the first therapy to integrate plasma separation and therapeutic adsorption within a single device. Therapeutic opportunities for

CardioDialysis include sepsis, life-threatening viral infections, neuroinflammatory disorders, and cardiovascular disease. The Company’s

development pipeline is comprised of ImmunePrep™ to optimize the delivery of therapeutic antibodies to treat cancer; ChemoPrep™

to enhance the targeted delivery of chemotherapy; and ChemoPure™ to reduce the toxicity of chemotherapy. To learn more about Sigyn

Therapeutics, visit: www.SigynTherapeutics.com

Forward-Looking

Statements

This

press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private

Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the Company’s

expectations regarding the proposed transaction with Sigyn Therapeutics, including the execution of a definitive license agreement, the

therapeutic potential of CardioDialysis™, the potential clinical benefits of combining ONP-002 and CardioDialysis™, and the

Company’s broader CNS platform strategy. The words “believe,” “expect,” “anticipate,” “intend,”

“estimate,” “project,” “potential,” “may,” “will,” “could,” “should,”

and similar expressions identify forward-looking statements. These statements are subject to a variety of risks, uncertainties, and other

factors that could cause actual results to differ materially, including the risk that a definitive agreement may not be executed, that

due diligence may reveal unfavorable results, that required approvals may not be obtained, and other risks described in the Company’s

most recent Form 10-K, Form 10-Q, and other filings with the U.S. Securities and Exchange Commission. The Company does not assume any

obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future developments,

or otherwise, except as required by law.

Although

the letter of intent provides that certain provisions are binding on the parties, it does not obligate the parties to consummate the

proposed transaction. The consummation of the proposed transaction remains subject to the negotiation, execution and delivery of a definitive

license agreement and the satisfaction or waiver of applicable closing conditions. There can be no assurance that any definitive agreements

will be entered into or that the proposed transaction will be consummated on the terms described herein or at all. Investors are cautioned

not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and are not guarantees of future

performance or outcomes.

Investor

& Media Relations

irth

Communications

800-383-4880

ir@oragenics.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

May 07, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 07, 2026

Entity File Number

001-32188

Entity Registrant Name

Oragenics,

Inc.

Entity Central Index Key

0001174940

Entity Tax Identification Number

59-3410522

Entity Incorporation, State or Country Code

Entity Address, Address Line One

9015

Town Center Parkway

Entity Address, Address Line Two

Suite

143

Entity Address, City or Town

Lakewood

Ranch

Entity Address, State or Province

Entity Address, Postal Zip Code

34202

City Area Code

813

Local Phone Number

286-7900

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock

Trading Symbol

OGEN

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration